Cancer vaccine

Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response, or, Secondary Resectability in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer

Retrieved on: 
Tuesday, August 22, 2023
Vaccine, DNA, Auckland City Hospital, Electroporation, Radiation, Circulating tumor DNA, University, PPM, Chief Justice of Hungary, Aes, Liquid biopsy, Cancer, Hope, Medicine, Doctor of Philosophy, Șaeș, MRD, NeXT, MRI, CD8, Patient, Sorafenib, EP, Immune system, CR, Cancer vaccine, Liver, CRS, Neoplasm, HCC, CMR, PD-1, Oncology, Pembrolizumab, Recurrence, SD, PR, Safety, Biopsy, Pharmaceutical industry, Medical imaging, Geneo Grissom

PLYMOUTH MEETING, Pa., Aug. 22, 2023 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced updated data from GT-30, an ongoing single-arm open-label multi-center Phase 1b/2a study in second-line advanced hepatocellular carcinoma (HCC). Previously, Geneos reported three patients to have achieved a complete response (CR) and a fourth patient to be cancer-free, whose liver and lung lesions shrank to become fully responsive to surgery and radiation (secondary resectability).

Key Points: 
  • Geneos reports today that four additional patients have achieved a complete molecular response (CMR) by ultrasensitive, third-generation, circulating tumor DNA (ctDNA) analysis.
  • By RECIST1.1, three of these four patients are durable partial responses (PR) and one a durable stable disease (SD).
  • By either RECIST1.1 or by ctDNA response, 11 of 32 evaluable have achieved either a complete response, partial response, or complete molecular response.
  • Cancer vaccines based on our DNA vaccine platform are showing complete responses in patients with late-stage, advanced cancer.

Global Cancer Vaccine Market, Vaccine Price, Dosage, Sales & Clinical Trials Outlook Report 2023-2029 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 18, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Vaccine, Antigen, Clinical trial, COVID-19, Indication, Cancer, Lung cancer, Genomics, Government, Malignancy, HIV disease progression rates, Immune system, Medicine, Cancer vaccine, Neoplasm, Ovarian cancer, Breast cancer, Pharmaceutical industry

The "Global Cancer Vaccine Market ,Vaccine Price, Dosage, Sales & Clinical Trials Outlook 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cancer Vaccine Market ,Vaccine Price, Dosage, Sales & Clinical Trials Outlook 2029" report has been added to ResearchAndMarkets.com's offering.
  • With the development of preventive as well as therapeutic cancer vaccines, it can be predicted that soon, cancer vaccines will hold a major share in the global cancer treatment market.
  • Therapeutic cancer vaccines are poised to revolutionize cancer treatment by leveraging the power of immune system against cancer cells.
  • Global Cancer Vaccine Market, Vaccine Price, Dosage, Sales & Clinical Trials Outlook 2029 Report Highlights:
    Cancer Vaccine Market Regional Trends Insight: 10 Countries
    Cancer Vaccine Market Trends Insight By Indication: 10 Indications
    Insight On Cancer Vaccine In Clinical Trials: > 400 Vaccines
    Insight On Cancer Vaccine Commercially available in Market: > 15 Vaccines
    Cancer Vaccines Clinical Trials By Company, Country, Indication & Phase

Syneos Health Dealmakers’ Intentions Survey Sees “Optimism” for M&A and Licensing Deals in 2023

Retrieved on: 
Tuesday, January 10, 2023
Gene editing, Mecum Dealmakers, Partnership, M&A, Cancer vaccine, Patent, Initial public offering, Environment, Research, RNA, COVID-19, Syneos Health, Fine chemical, Vaccine, Sales

MORRISVILLE, N.C., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 13th annual Dealmakers’ Intentions Survey.

Key Points: 
  • MORRISVILLE, N.C., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 13th annual Dealmakers’ Intentions Survey.
  • In its 13th Annual Dealmakers’ Intentions Survey, Syneos Health found that dealmaker sentiment at the end of 2022 pointed toward a possible rebound in M&A and licensing deals, driven partly by buyers’ need to shore up their base of marketed assets ahead of patent expirations on blockbuster drugs.
  • Interest in cell and gene therapy technologies remains strong heading into 2023, with 65 percent of survey respondents stating that they are actively seeking deals in this area.
  • Submit a request to have a Syneos Health Consulting team member present survey results and implications for your business.

Global Cancer Vaccine Partnering Terms and Agreements Report and Directory 2022: Contract Documents for Over 350 Deals - Trends, Key Players, Top Deal Values, and Deal Financials 2010-2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 13, 2022
Pharmaceutical, Health, Oncology, Hyperlink, Mecum Dealmakers, Chapter Five, Chapter Three, Sale, Chapter One, Cancer vaccine, Research, A-Z, Chapter Four, Securities & Exchange Commission of Pakistan, Confidentiality, Agreement, Chapter Six, Record, Intellectual property, Orientation, It Takes Two, Pharmaceutical industry, Publishing, Property management, Vaccine, Lease, Petroleum, Practice of law

The "Global Cancer Vaccine Partnering Terms and Agreements 2010-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cancer Vaccine Partnering Terms and Agreements 2010-2022" report has been added to ResearchAndMarkets.com's offering.
  • The Global Cancer Vaccine Partnering Terms and Agreements 2010-2022 report provides comprehensive access to available deals and contract documents for over 350 Cancer Vaccine deals.
  • The report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.
  • In Global Cancer Vaccine Partnering Terms and Agreements 2010-2022, the available deals are listed by:

AIVITA Biomedical CEO Dr. Hans Keirstead Wins Innovator of the Year Award

Retrieved on: 
Wednesday, September 14, 2022
Cancer vaccine, COVID-19, Neoplasm, Orange County Business Journal, Private Securities Litigation Reform Act, Industry, Melanoma, Glioblastoma, Survival, Forward-looking statement, Patient, Multimedia, Immune system, Cancer, Communication, Financial Times and McKinsey Business Book of the Year Award, Vaccine

IRVINE, Calif., Sept. 14, 2022 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced that chairman and CEO Hans Keirstead, Ph.D., has received the Orange County Business Journal's 2022 Innovator of the Year Award.

Key Points: 
  • IRVINE, Calif., Sept. 14, 2022 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced that chairman and CEO Hans Keirstead, Ph.D., has received the Orange County Business Journal's 2022 Innovator of the Year Award.
  • The annual award recognizes Orange County innovators who are creating game-changing ideas, processes, products, services, and business models.
  • The personal cancer immunotherapy trains the patient's immune system to seek out the antigenic signature of their specific cancer's tumor-initiating cells.
  • In the past 12-months Dr. Keirstead also led the development of a novel personal vaccine kit for the prevention of COVID-19.

NEUVOGEN Appoints Stephen A. Sherwin, M.D. to its Scientific Advisory Board

Retrieved on: 
Monday, July 25, 2022
National, Genentech, University, Clinical research, President's Council of Advisors on Science and Technology, American College, GVAX, Internal medicine, Third Rock Ventures, Physician, Clinical professor, SAN, San Francisco General Hospital, Cancer, CAR, Neoplasm, Partnership, Biogen, National Cancer Institute, Board, Therapy, Neon, Immune system, Partner, United States Air Force Scientific Advisory Board, Hospital, Technology, University of California, San Francisco, Immunotherapy, Patient, BioNTech, Yale University, Harvard Medical School, SAB, American College of Physicians, Amgen, Drug development, Oncology, Cancer vaccine, Antigen, Biotechnology Innovation Organization, Vaccine, Pharmaceutical industry, Medicine, Biology, Medicine, Science

SAN DIEGO, July 25, 2022 /PRNewswire/ --NEUVOGEN, an immuno-oncology company with a next-generation cancer vaccine platform, is pleased to announce the appointment of Stephen A. Sherwin, M.D., to the company's Scientific Advisory Board (SAB).

Key Points: 
  • SAN DIEGO, July 25, 2022 /PRNewswire/ --NEUVOGEN, an immuno-oncology company with a next-generation cancer vaccine platform, is pleased to announce the appointment of Stephen A. Sherwin, M.D., to the company's Scientific Advisory Board (SAB).
  • "We are extremely honored to have Dr. Sherwin join NEUVOGEN's Scientific Advisory Board" said Todd Binder, Chief Executive Officer of NEUVOGEN.
  • "I am excited to join the NEUVOGEN SAB and bring my past experience in immunotherapy and cancer vaccines to NEUVOGEN.
  • By building upon previous cancer vaccine efforts, NEUVOGEN hopes its vaccines can fulfill that potential" said Dr. Sherwin.

Cancer Vaccines Analytical Tool 2022: A Must-have for Any Business Developer, BI/CI Operative or Clinical Developer who Needs to be on Top of this Hot and Fast Moving Area of Immune-Oncology - ResearchAndMarkets.com

Retrieved on: 
Monday, June 27, 2022
Pharmaceutical, Health, Oncology, Scale (analytical tool), Cancer vaccine, International, Chemistry (relationship), SITC, Biomarker, ASH, Industry, Cancer, AACR, EHA, Business development, ESMO, EORTC, CMIT, Environment, Time, Tool, Table, ASCO, BIO, Medical imaging

and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts).

Key Points: 
  • and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts).
  • Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.
  • We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials.
  • This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.

Global Cancer Vaccine Platforms Markets Report 2022: Technology & Competitive Landscape, Patent Watch, Future Prospects, Recommendations & Conclusion - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 11, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Molecular biology, Pembrolizumab, Investment, Merck, European Commission, HNSCC, Patient, BioNTech, PCV, Cancer, Cancer vaccine, DNA, Biochemistry, Vaccine, Organic acid, Cervical cancer, Prostate cancer, Sanofi, Genetics, B cell, Protein, Technology, IP, Neoplasm, Acquisition, Royal commission, Pharmaceutical industry, Northwest Biotherapeutics

Major factors driving the cancer vaccine market growth include the increasing number of cancer cases, rising investments and funding by government organizations for developing cancer vaccines, and technological developments in cancer vaccines platforms.

Key Points: 
  • Major factors driving the cancer vaccine market growth include the increasing number of cancer cases, rising investments and funding by government organizations for developing cancer vaccines, and technological developments in cancer vaccines platforms.
  • However, recent advancements in the fields of molecular biology, genetics, biochemistry, and immunology have renewed interest and allowed the development of promising cancer vaccine candidates.
  • In this report, different vaccine platforms such as nucleic acids, proteins, cell-based, oncolytic virus-based platforms, and antigenic technologies are provided.
  • Most of the startup players are working around vaccine technologies (recombinant cancer vaccines, whole-cell cancer vaccines, DNA cancer vaccines, and other technologies), treatment method (preventive vaccine and therapeutic vaccine), application (prostate cancer, cervical cancer), and other applications.

Global Cancer Vaccine Partnering Terms and Agreements 2010-2021: Comprehensive Access to Available Deals and Contract Documents for 330 Cancer Vaccine Deals - ResearchAndMarkets.com

Retrieved on: 
Friday, March 18, 2022
Pharmaceutical, Health, Oncology, Cancer vaccine, A-Z, Record, Hyperlink, Chapter Six, Securities & Exchange Commission of Pakistan, SEC, Chapter One, Agreement, Chapter Four, U.S. Securities and Exchange Commission, Review, Chapter Three, Chapter Five, Orientation, It Takes Two, Pharmaceutical industry

The Global Cancer Vaccine Partnering Terms and Agreements 2010-2021 report provides comprehensive access to available deals and contract documents for over 330 Cancer Vaccine deals.

Key Points: 
  • The Global Cancer Vaccine Partnering Terms and Agreements 2010-2021 report provides comprehensive access to available deals and contract documents for over 330 Cancer Vaccine deals.
  • The report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.
  • Chapter 6 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2010.
  • Global Cancer Vaccine Partnering Terms and Agreements 2010-2021 provides the reader with the following key benefits:
    Insight into terms included in a Cancer Vaccine partnering agreement, with real world examples
    In Global Cancer Vaccine Partnering Terms and Agreements 2010-2021, the available deals are listed by:

Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

Retrieved on: 
Monday, March 14, 2022
Forward-looking statement, Society for Immunotherapy of Cancer, ODD, Time, Phenotype, Services General Administration and Coordination Department, Government of Sindh, Lymphatic system, GLOBE, Research and development, U.S. Securities and Exchange Commission, Patient, Society, Private Securities Litigation Reform Act, CD33, Investment, NMDP, FDA, Aerobic treatment system, Risk, Science, Health, Annual general meeting, National Marrow Donor Program, Immunotherapy, Acute myeloid leukemia, ASH, Adult, Standard of care, Administration, Security (finance), IND, Clinical trial, Food, Gene editing, Company, Fast Track, Growth, Cancer vaccine, Engineering, Medicine, R, AML, SITC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Stem cell, Medical device, Vaccine, Pharmaceutical industry, Lithium, Gemtuzumab ozogamicin, G&A

CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2021, and provided a business update.

Key Points: 
  • CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2021, and provided a business update.
  • VBP101 is a Phase 1/2a multicenter, open-label, first-in-human study of VOR33 in participants with AML who are at risk of relapse.
  • COVID-19-related issues delayed trial site readiness resulting in enrollment delays, which are being mitigated by the opening of additional trial sites.
  • VOR33-CLL1 + VCAR33-CLL1 Treatment System: Vor Bio continues to make progress on this new multiplex-edited program, previously announced in November 2021.